αvβ6 integrin is an old face on a new shelf. The same heterodimer that flags wound-healing fibroblasts in normal tissue gets aberrantly upregulated across a long list of epithelial cancers, and the recent clinical imaging tracer [68Ga]Ga-Trivehexin has shown the integrin sitting on pancreatic, head and neck, lung, breast, and cervical tumors in living patients. The diagnostic half of the theranostic pair therefore exists. The therapeutic half does not. The αvβ6-targeted Lu-177 radioligands you can find in the literature are early stage and mostly monovalent, which is a problem because the receptor benefits more than most from multivalent engagement.
A radiochemistry team published May 27 in Molecular Pharmaceutics ↗ what reads as a careful linker-optimization scan for a Lu-177 trimer. The construct uses three copies of the cyclic nonapeptide Tyr2 (sequence c(YRGDLAYp(NMe)K), an αvβ6-selective ligand previously characterized at nanomolar affinity) tethered to the tetrafunctional chelator DOTPI by copper-catalyzed click chemistry. The fourth arm of DOTPI holds the radiometal. Four PEG linker lengths went in: PEG0, PEG3, PEG7, and PEG11. The point of the scan was to find the linker geometry that lets the three peptide arms reach the receptor independently without the trimer collapsing on itself in plasma.
The in vitro data anchored the scan but did not select between linkers. All four constructs landed at log D 7.4 around -2 (similar lipophilicity profile) and showed ELISA affinities to αvβ6 in the 0.2 to 0.5 nM band (essentially indistinguishable). The PEG length apparently does not change what the receptor sees when the peptide arm gets there.
What it does change is what happens after. In αvβ6-positive H2009 lung adenocarcinoma cells, longer linkers gave markedly higher and longer-lasting receptor-mediated uptake and internalization, consistent with the trimer engaging multiple receptor copies cooperatively when the geometry allows it. In H2009 xenograft mice, the same trend translated. PEG linkers reduced early blood-pool activity and increased tumor uptake at 24 hours post-injection. Beyond PEG7 the gains plateau. The authors took the PEG7 trimer (designated P7) as the lead.
Two further measurements give P7 a clean pharmacological window. Selectivity over the other αv-class integrin subtypes ran 65 to 671 fold (the spread reflects which subtype is being compared against; the closest cousin sits at the low end and the others further away). Small-animal SPECT imaging showed tumor retention for up to six days, which is a useful match to the Lu-177 physical half-life of 6.7 days for therapeutic dose deposition. αvβ6-blocking experiments confirmed that the radiotoxicity to tumor cells in vitro was receptor-mediated rather than from off-target localization.
The kidney number is the other half of the story. Radiopeptides delivered by intravenous injection routinely deposit in proximal tubules through receptor-mediated reabsorption, and the dose that the kidney sees often sets the upper bound on what the tumor can be given. Coinjection of gelofusine (a 4% succinylated gelatin solution used clinically as a plasma volume expander) reduced renal retention by up to 92% in the H2009 xenograft model. This is not a new trick: gelofusine has been used in peptide receptor radionuclide therapy since the somatostatin-analog era to reduce kidney dose in Lu-177 DOTATATE delivery. What is new is that it works as advertised on a PEGylated trimer with this much avidity and this long a tumor retention.
The piece on the table is preclinical. There is no patient data and no Investigational New Drug filing yet. What the work does provide is a properly characterized lead and the linker-scan methodology that picked it, which is exactly what αvβ6 theranostics ↗ has been missing while the imaging side moves toward routine clinical use.